Company intelligence / Profile preview

SBI ALApharma

Canada
Ownership
Private
Development stage
Other
01

Overview

SBI ALApharma Canada focuses on the commercialization of intraoperative tumor visualization using a combination of 5-Aminolevulinic acid as a photosensitizer and proprietary fluorescence imaging devices. Their main product enables real-time identification of tumors during surgery, improving surgical outcomes. The company has at least one clinical trial ongoing and leverages technology from both photonamic and MolecuLight.

Therapeutic areas
EndocrinologyHematologyOncologyNeurologyInfectious Diseases
Modalities
Small moleculePhotosensitizer
Industry
Biotech
02

Partnerships

PhotonamicMolecuLight

Beyond the preview

Go deeper on SBI ALApharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBI ALApharma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call